HC Wainwright Issues Positive Estimate for ADVM Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Adverum Biotechnologies to ($0.84) per share, an improvement from the prior estimate of ($1.19), and maintains a "Buy" rating with a target price of $30.00.
• The company's recent quarterly earnings reported a loss of ($2.34) per share, missing estimates of ($2.24) by $0.10.
• Adverum Biotechnologies has seen a significant increase in institutional investments, with approximately 48.17% of the stock being owned by institutional investors.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Equities research analysts at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for shares of Adverum Biotechnologies in a report issued on Wednesday, August 13th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will earn ($0.84) per share for the quarter, up from their previous forecast of ($1.19). HC Wainwright currently has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Adverum Biotechnologies' current full-year earnings is ($4.92) per share. HC Wainwright also issued estimates for Adverum Biotechnologies' Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($4.87) EPS, FY2026 earnings at ($3.21) EPS, FY2027 earnings at ($3.22) EPS, FY2028 earnings at ($2.99) EPS and FY2029 earnings at ($2.12) EPS.

ADVM has been the subject of several other reports. Mizuho dropped their price objective on Adverum Biotechnologies from $16.00 to $12.00 and set an "outperform" rating for the company in a research report on Thursday, June 26th. Chardan Capital restated a "buy" rating and set a $33.00 price objective on shares of Adverum Biotechnologies in a research report on Wednesday, August 13th. Finally, Royal Bank Of Canada dropped their price objective on Adverum Biotechnologies from $5.00 to $4.00 and set a "sector perform" rating for the company in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $19.75.

Adverum Biotechnologies Price Performance

Shares of ADVM stock traded up $0.07 on Friday, hitting $2.93. 100,939 shares of the company's stock were exchanged, compared to its average volume of 111,141. Adverum Biotechnologies has a 12 month low of $1.78 and a 12 month high of $8.56. The stock has a market cap of $61.47 million, a P/E ratio of -0.37 and a beta of 0.77. The company has a 50 day moving average of $2.51 and a 200 day moving average of $3.23.

Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($2.34) earnings per share for the quarter, missing the consensus estimate of ($2.24) by ($0.10).

Hedge Funds Weigh In On Adverum Biotechnologies

Several large investors have recently bought and sold shares of ADVM. Y Intercept Hong Kong Ltd bought a new position in Adverum Biotechnologies in the second quarter valued at about $45,000. Wells Fargo & Company MN raised its position in Adverum Biotechnologies by 27.8% in the fourth quarter. Wells Fargo & Company MN now owns 12,240 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 2,659 shares during the last quarter. XTX Topco Ltd bought a new position in Adverum Biotechnologies in the second quarter valued at about $64,000. Qube Research & Technologies Ltd bought a new position in Adverum Biotechnologies in the second quarter valued at about $66,000. Finally, Marshall Wace LLP bought a new position in Adverum Biotechnologies in the second quarter valued at about $107,000. 48.17% of the stock is currently owned by institutional investors.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.